Results 131 to 140 of about 38,115 (239)

Registries on transcatheter edge‐to‐edge repair in heart failure: Current evidence and future perspectives

open access: yesEuropean Journal of Heart Failure, EarlyView.
Clinical evidence in transcatheter edge‐to‐edge valve repair. EF, ejection fraction; eGFR, estimated glomerular filtration rate; EROA, effective regurgitant orifice area; GDMT, guideline‐directed medical therapy; HF, heart failure; HHF, hospitalization for heart failure; LVEDV, left ventricular end‐diastolic volume; MR, mitral regurgitation; MVARC ...
Gianluigi Savarese   +13 more
wiley   +1 more source

Effect of strategies to improve interhospital transports of critically ill patients on safety and costs: protocol for a systematic review and meta-analysis. [PDF]

open access: yesBMJ Open
Severino F   +8 more
europepmc   +1 more source

Sacubitril/valsartan versus valsartan initiation in patients naïve to renin–angiotensin system inhibitors: Insights from PARAGLIDE‐HF

open access: yesEuropean Journal of Heart Failure, EarlyView.
Changes in N‐terminal pro‐B‐type natriuretic peptide and assessment of clinical endpoints according to prior exposure to renin–angiotensin system inhibitors in the Pre‐specified substudy of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE‐HF).
Nina Nouhravesh   +14 more
wiley   +1 more source

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Baseline characteristics for the vericiguat global study in participants with chronic heart failure (VICTOR) trial. ARNI, angiotensin receptor/neprilysin inhibitor; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; GDMT, guideline‐directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection ...
Clara I. Saldarriaga   +21 more
wiley   +1 more source

Potential Efficacy of the MOVERS Professional Development Programme: A Pilot Randomised Controlled Trial. [PDF]

open access: yesChild Care Health Dev
Kazmierska-Kowalewska KM   +5 more
europepmc   +1 more source

Cardiac rhythm devices in heart failure with reduced ejection fraction – role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision‐making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices
Biykem Bozkurt   +15 more
wiley   +1 more source

Paths to Common Ground in ASD. [PDF]

open access: yesAutism Res
Karin E   +4 more
europepmc   +1 more source

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients
Jawad H. Butt   +18 more
wiley   +1 more source

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Jawad H. Butt   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy